🔗 Share this article

This year's Nobel Prize in medical science was granted for transformative findings that illuminate how the immune system targets dangerous pathogens while protecting the body's own cells.

A trio of renowned scientists—Japan's Prof. Sakaguchi and US scientists Mary Brunkow and Fred Ramsdell—received this honor.

Their work identified specialized "sentinels" within the immune system that remove malfunctioning immune cells capable of attacking the organism.

These findings are now enabling innovative therapies for autoimmune diseases and malignancies.

The laureates will share a prize fund valued at 11m Swedish kronor.

Crucial Findings

"The research has been decisive for understanding how the immune system operates and why we do not all suffer from serious self-attack conditions," stated the head of the award panel.

This team's research explain a core mystery: In what way does the immune system protect us from countless invaders while leaving our healthy cells intact?

Our body's protection system employs white blood cells that scan for indicators of disease, including pathogens and bacteria it has not met before.

These defenders employ detectors—called recognition units—that are produced by chance in countless combinations.

This gives the defense network the capacity to fight a broad range of invaders, but the unpredictability of the mechanism unavoidably produces white blood cells that may target the host.

Protectors of the Immune System

Scientists previously understood that a portion of these harmful white blood cells were eliminated in the thymus—where immune cells mature.

The latest award honors the identification of regulatory T-cells—described as the body's "security guards"—which travel through the system to disarm other defenders that attack the healthy cells.

We know that this process fails in self-attack conditions such as juvenile diabetes, MS, and RA.

A Nobel panel stated, "These findings have laid the foundation for a novel area of research and accelerated the creation of new therapies, for example for tumors and immune disorders."

Regarding cancer, regulatory T-cells block the body from attacking the tumor, so research are focused on reducing their quantity.

For autoimmune diseases, experiments are testing increasing regulatory T-cells so the body is not being harmed. A comparable method could also be useful in reducing the risks of transplanted organ rejection.

Innovative Studies

Prof Shimon Sakaguchi, from Osaka University, performed tests on mice that had their immune gland removed, leading to autoimmune disease.

He demonstrated that introducing immune cells from other animals could prevent the illness—implying there was a system for blocking defenders from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Fred Ramsdell, currently at Sonoma Biotherapeutics in San Francisco, were investigating an genetic autoimmune disease in rodents and humans that led to the discovery of a genetic factor vital for how T-regs function.

"The pioneering research has uncovered how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the body's own tissues," commented a leading biological science specialist.

"This work is a remarkable illustration of how basic physiological research can have broad implications for human health."